Compare EXG & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EXG | IDYA |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.9B |
| IPO Year | N/A | 2019 |
| Metric | EXG | IDYA |
|---|---|---|
| Price | $9.30 | $35.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $49.42 |
| AVG Volume (30 Days) | 533.2K | ★ 903.8K |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 8.27% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $214,834,000.00 |
| Revenue This Year | N/A | $2,434.86 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 5377.66 |
| 52 Week Low | $6.78 | $13.45 |
| 52 Week High | $8.15 | $36.61 |
| Indicator | EXG | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 58.49 | 65.67 |
| Support Level | $9.14 | $33.14 |
| Resistance Level | $9.31 | $36.61 |
| Average True Range (ATR) | 0.12 | 1.54 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 90.68 | 83.91 |
Eaton Vance Tax-Mgd Glbl Div Eq Inc is a diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary focus of the fund is capital appreciation. It invests in a diversified portfolio of domestic and foreign common stocks, emphasizing dividend-paying stocks. It writes call options on one or more U.S. and foreign indices for a portion of the value of its common stock portfolio to generate current cash flow from the options premium received. Its portfolio of investments consists of capital markets, banks, internet and direct marketing retail, biotechnology, media, oil, gas, consumable fuels, and other sectors.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.